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Abstract: Bifidobacteria play a vital role in human nutrition and health by shaping and maintaining
the gut ecosystem. In order to exert a beneficial effect, a sufficient population of bifidobacteria must
colonise the host. In this study, we developed a miniaturised high-throughput in vitro assay for
assessing the colonising ability of bacterial strains in human cells. We also investigated a variety
of components isolated from different milk sources for their ability to increase the adherence of
Bifidobacterium longum subsp. infantis ATCC 15697, a common member of the gastrointestinal
microbiota of breastfed infants, to HT-29 cells. Both conventional and miniaturised colonisation
assays were employed to examine the effect of 13 different milk-derived powders on bacterial
adherence, including positive controls which had previously resulted in increased bifidobacterial
adherence (human milk oligosaccharides and a combination of 3′- and 6′-sialylactose) to intestinal
cells. Immunoglobulin G enriched from bovine whey and goat milk oligosaccharides resulted
in increased adhesion (3.3- and 8.3-fold, respectively) of B. infantis to the intestinal cells and the
miniaturised and conventional assays were found to yield comparable and reproducible results.
This study highlights the potential of certain milk components to favourably modulate adhesion of
bifidobacteria to human intestinal cells.
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1. Introduction
Milk is a complex and complete source of bioactive molecules that help to protect the newborn
against infectious diseases and promote development, while selectively enriching a beneficial gut
microbiota. Therefore, milk influences infant nutrition and microbial nutrition, which in combination
promote infant health. Analyses of the infant microbiome indicate that breast milk selects for a highly
adapted intestinal microbiota, dominated by bifidobacteria [1]. Indeed, the most commonly detected
species in breastfed infants include Bifidobacterium longum, B. infantis, B. breve, and B. bifidum [2].
Bifidobacteria are associated with a number of health-related benefits for the host including inhibiting
the growth of pathogenic organisms, modulating mucosal barrier function and promoting appropriate
immunological and inflammatory responses [3,4]. Based on these therapeutic effects, bifidobacteria
are a popular choice as probiotics. In order to exert a beneficial effect, a sufficient population of
bifidobacteria must colonise the host, and therefore, initially adhere to host cell components [5].
There are two approaches most traditionally employed to modulate the gut microbiota; delivery of
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live bacteria (probiotics) within a food source, or the use of specific prebiotics (inulin, fructo- and
galactooligosaccharides), which are known to survive gastric transit and are fermented in the colon by
beneficial bacteria, thus promoting their growth [6].
More recently, studies have suggested that components in human milk, such as oligosaccharides,
may contribute not only to the selective growth of commensal bacteria but also to their specific
adhesive ability. Gonzalez et al. [7] demonstrated that growth of B. longum in defatted human milk
leads to the genetic up-regulation of putative type II glycoprotein binding fimbriae, which have been
implicated in attachment and colonisation. Chichlowski et al. [8] demonstrated that the growth of
B. longum subsp. infantis ATCC 15697 on human milk oligosaccharides (HMO) as the sole carbon
source increased bacterial adherence to HT-29 intestinal cells. Kavanaugh et al. [9] showed that
treatment of B. longum subsp. infantis ATCC 15697 with a mixture of the HMO, 3′- and 6′-sialyllactose
(3′SL and 6′SL, respectively) substantially increased bacterial adhesion (up to 9.8-fold) to HT-29 cells.
Moreover, transcriptomic analysis revealed that the increased adherence phenotype of the strain
resulting from exposure to HMO is likely multi-faceted, involving transcription factors, chaperone
proteins, adhesion-related proteins, and a glycoside hydrolase [9]. Garrido et al. [10] found that
solute binding proteins produced by B. longum subsp. infantis ATCC 15697 had a binding affinity
for mammalian carbohydrate structures including Lewis antigens, polylactosamines and globotriose
(Gb3) and structures found in colonic mucins, suggesting that B. infantis may also interact with such
structures on the epithelial cells.
Examining the effect of HMO structures on bifidobacterial colonisation in vivo may prove difficult
as only certain structures are currently available and not the entire range of HMO found in human
milk. Therefore, investigation of other milk sources for components with adhesion promoting
capabilities may be an attractive alternative. For instance, domestic animal milk components including
oligosaccharides may have biological functions similar to those of human milk. In addition, current
methods for investigation of bacterial colonisation are time-consuming and require a high quantity of
sample for testing. As a result, there is a need to develop high-throughput (HTP) techniques which
can quickly define the colonising ability of bacterial strains to human cell lines and which require
substantially lower sample quantities. This is particularly important as isolation yields of compounds
from natural sources are often too low for investigation in such bioassays.
The aim of the current study was to investigate the changes in adhesion of B. longum subsp.
infantis ATCC 15697, a model consumer of HMO in the infant gastrointestinal (GI) tract, to HT-29 cells
following exposure to a panel of milk-derived components. We have also developed a miniaturised
HTP method for screening bacterial interactions with cells and compared it with a conventional
assay. In total, 13 different milk powders derived from a variety of sources were investigated for
their ability to increase bacterial adherence to HT-29 cells, using both conventional and miniaturised
colonisation assays. Free oligosaccharides and some of the major milk glycoproteins comprised the
main components of these powders and their effects were compared with commercially available
3′- and 6′–sialyllactose and HMO, which were previously shown to increase bifidobacterial adherence
to HT-29 cells.
2. Materials and Methods
2.1. Materials
The oligosaccharides 3′-sialylactose (3′-SL) and 6′-sialylactose (6′-SL) were purchased from
Carbosynth Ltd. (Berkshire, UK). Beneo Orafti P95 (oligofructose) was kindly provided by Beneo Orafti
(Oreye, Belgium). Bovine β-casein (β-C) and β-lactoglobulin (β-L) were purchased from Merck
(Darmstadt, Germany). Glycomacropeptide (GMP), with a maximum lactose content of 1% and
containing approximately 8.5% sialic acid was kindly provided by Agropur Ingredients (Eden Prairie,
MN, USA). Lyophilised Bovine Lactoferrin (LF) and lyophilised Immunoglobulin G enriched powder
(IGEP) isolated from bovine whey were kindly provided by Upfront Chromatography (Copenhagen,
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Denmark). Lacprodan® MFGM-10 from whey protein concentrate with a maximum lactose content
of 3%, containing 2% sialic acid and 5% IgG was kindly provided by Arla Food Ingredients
(Viby J, Denmark). Lacprodan® PL-20 with a maximum lactose content of 10%, containing a minimum
of 16% phospholipids was also kindly provided by Arla Food Ingredients. The human colonic
adenocarcinoma HT-29 cell line was used as a model of the human intestinal epithelial layer and was
purchased from the American Type Culture Collection (ATCC, Middlesex, UK).
2.2. Generation of Milk-Derived Powders
All powders used in the study and their sources are listed in Table 1. For human milk
oligosaccharides (HMO), human milk was kindly donated by the Irvinestown Human Milk Bank
(Co. Fermanagh, Ireland). For goat milk oligosaccharides (GMO), mature milk from goats was kindly
donated by Ardsallagh Goat Farm (Carrigtwohill, County Cork). All samples were stored at−80 ◦C on
arrival. To generate low molecular weight fractions, the milks were initially defatted by centrifugation
at 4 ◦C, for 20 min at 3850× g. Caseins were then precipitated by adjusting the pH to 4.6, followed
by centrifugation at 3850× g at 25 ◦C for 20 min. After neutralisation (by adjusting the pH to 6.7),
large peptides and whey proteins were removed by ultrafiltration using a 5 kg/mol molecular weight
cut off (MWCO) membrane (Millipore Helicon S10 Spiral Cartridge; Millipore). The permeates were
freeze-dried and, to separate the lactose from the oligosacchrides, 100 mL of a 10% solution of each
powder were applied to a BioGel P2 size exclusion column (92 × 5 cm; Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) and eluted with deionised water at 3 mL/min. The 14 mL fractions collected
were analysed for lactose, 3-SL and 6-SL using high pH anion exchange chromatography with pulsed
amperometric detection (HPAEC-PAD) as detailed below, and peptide concentration was determined
by the Bradford assay [11]. Peptide-free and low-trace lactose (<80 mg/L) fractions were pooled and
freeze-dried to give an oligosaccharide-enriched fraction (referred to as HMO and GMO for human
and goat milk, respectively).
Table 1. List of milk-derived components used in study.
Powder Abbreviation Source
Goat milk oligosaccharides GMO Isolated in-house
Bovine milk oligosaccharides BMO Isolated in-house
Human milk oligosaccharides HMO Isolated in-house
3′-sialyllactose and 6′-sialyllactose 3′ and 6′ SL Merck
Glycomacropeptide GMP Agropur foods international
Lactoferrin LF Upfront Chromatography A/S
β-casein β-C Merck
Lacprodan® MFGM-10 MFGM-10 Arla food ingredients
β-lactoglobulin β-L Merck
Lacprodan® PL-20 PL-20 Arla food ingredients
Butter milk fraction BF Isolated in-house
P95 P95 Beneo Orafti
Immunoglobulin G Enriched Powder IGEP Upfront Chromatography A/S
For bovine milk oligosaccharides (BMO), mother liquor (Glanbia plc, Co., Kilkenny, Ireland)
was treated as described above. Following this, fractions low in lactose (<30 mg/L) from a number
of separate runs were pooled and freeze-dried to give a bovine oligosaccharide enriched powder
which still contained residual peptides. A 5% filtered solution (100 mL) of this powder was applied
to a Nucleosil C18 reverse phase column (250 × 8 mm) on a 2695 Waters Alliance HPLC system
(Waters Corporation, 34 Maple St, Milford, MA, USA) using deionised water as the eluent at a flow rate
of 2 mL/min, which resulted in the binding of peptides to the column. After the sample was applied,
the column was washed with one column volume of water. The sample flow-through and column
wash were eluted, collected and freeze-dried to give an oligosaccharide-enriched and peptide-free
fraction referred to as BMO.
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For buttermilk fractions (BF), milk from Holstein-Friesian cattle was obtained from the bulk tank
located at the milking parlour at the Teagasc Food Research Centre, Moorepark (Fermoy, Co., Cork,
Ireland). Isolation of the buttermilk fraction was performed as previously described [12]. In brief,
cream and milk fat globules were separated from the milk using a FT15 disc bowl centrifuge (Armfield
Ltd., Ringwood, UK) and the cream was stored at 4 ◦C for 12–24 h. After chilling, the cream was
churned using a mixer to produce butter and buttermilk. The buttermilk was then passed through
glass wool (Merck) to remove minute butter granules. Washed cream was produced as described
previously [13,14]. Briefly, warm deionised water (37 ◦C) was added to the cream at a ratio of 1:10 and
the mixture was added to the FT15 disc bowl centrifuge. This process was repeated twice, and the
washed cream was then used to produce buttermilk as described above. A 5 kg/mol Viva-Flow 200
(Sartorius®, Göttingen, Germany) crossflow filtration system was used to separate lactose from the high
molecular weight components leaving a sample enriched in glycoproteins and glycolipids. The sample
was then lyophilised and the dry powder stored in a desiccator at room temperature. The final sample
contained 0.223 mg/g of lactose which was quantified as previously described [15].
2.3. Milk Oligosaccharides Analysis
Oligosaccharide-enriched fractions were diluted in water and analysed in order to quantify levels
of lactose, 3′-SL and 6′-SL using a Dionex ICS-3000 Series system (Dionex Corporation, Sunnyvale,
CA, USA) equipped with an electrochemical detector. Samples were separated on a CarboPac PA100
column (250 × 4 mm) equipped with a guard column using the following gradient; 95% 100 mM
NaOH (Eluent A) and 5% 100 mM NaOH with 500 mM NaAc (Eluent B) for 3 min, 88% eluent A
and 12% eluent B for 10 min, and 50% eluent A and 50% eluent B for 17 min for a 30 min separation.
The column was re-equilibrated for 15 min with 95% eluent A and 5% eluent B after each separation.
2.4. Bacterial Strains and Culture
Bacterial culture conditions were maintained as previously described [9]. Bifidobacterium longum
subsp. infantis ATCC® 15697™ (B. infantis) was obtained from the American Type Culture Collection
(ATCC, Middlesex, UK). and the strain was stored in deMan Rogosa Sharpe (MRS) (Difco, Sparks,
MD, USA) broth containing 50% glycerol at −80 ◦C. The strain was cultured twice in MRS media
supplemented with L-cysteine (0.05% w/v) prior to use and was routinely grown overnight at 37 ◦C
under anaerobic conditions generated using the Anaerocult A system (Merck, Dannstadt, Germany).
For assays, B. infantis was incubated alone or in combination with each powder for 1 h and the
bacteria were serially diluted and enumerated by spot plating on MRS agar to determine bacterial
numbers. To determine the mid-exponential growth phase, the culture was monitored by measuring
the absorbance at 600 nm (OD600 nm) at intervals during growth.
2.5. Mammalian Cell Culture
Typically, HT-29 cells were grown in McCoy′s 5A modified medium (Merck) supplemented with
10% fetal bovine serum (FBS), which were maintained in 75 cm2 tissue culture flasks and incubated at
37 ◦C in 5% CO2 in a humidified atmosphere. For conventional 12-well plate preparations, once the
cells were confluent (approximately 80–90%), cells were passaged into 12 well plates. For the assays,
cells in 75 cm2 flasks were trypsinised and seeded into a 12-well tissue culture plate (Sarstedt Ltd.,
Wexford, Ireland) at a density of 1 × 105 cells/mL between passages 15–21 and cells were used once
fully confluent (approximately 4 × 106 cells/well at day 5–7). The media was changed every other
day and supplemented with 2% FBS 24 h prior to use. For miniaturised 48-well plate preparations,
the cells were grown and passaged as above. Cells were trypsinised and seeded into a 48-well tissue
culture plate (Sarstedt Ltd., Wexford, Ireland) at a density of 1 × 105 cells/mL between passages 15–21
and cells were used once fully confluent (approximately 2 × 106 cells/well).
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2.6. Exposure of Bacteria to Milk-Derived Powders
Exposure of the bacteria to milk-derived powders (Figure 1) was performed as previously
described with minor modifications [9]. Bacteria were used at mid-exponential growth phase (18 h) and
the OD600nm was adjusted to 0.3 at the start of the assay, after which the cells were cultured for 1.5–2 h
and used once an OD600nm of 0.5 was reached (corresponding to approximately 1.6 × 108 CFU/mL).
Bacterial cells were washed twice with PBS by centrifugation. Cell pellets were re-suspended to a final
OD600nm of 0.5 in McCoy’s 5A tissue culture media supplemented with 2% FBS and either 5 mg/mL
of HMO or a total of 5 mg/mL of a mixture of 3′ and 6′ SL at a ratio of 1:1 (after filtration using a
0.45 um filter, Sarstedt Ltd.). A non-supplemented negative control was also included, i.e., bacteria
resuspended in McCoy’s 5A tissue culture media alone. Bacterial suspensions were then incubated
for 1 h at 37 ◦C under anaerobic conditions. Following this, bacteria were harvested by centrifugation
(3850× g, 5 min), the supernatants removed, and pellets were washed three times in PBS and then
re-suspended in non-supplemented McCoy’s media prior to use in the adhesion assays. For the
miniaturised bacterial assay exposures, B. infantis was cultured and prepared as above except cell
pellets were re-suspended to a final OD600nm of 0.25 in non-supplemented or supplemented McCoy’s
5A tissue culture media. A final concentration of 5 mg/mL of GMO, BMO, P95 and HMO was used
plus a 5 mg/mL mixture of 3′ and 6′-SL at a ratio of 1:1. The results obtained for HMO and 3′ and
6′ SL were assessed and compared to ensure equivalence against the conventional assay (Figure 2).
The same results were also included with the results obtained for the other oligosaccharides, GMO,
BMO and P95 (Figure 3). A final concentration of 5 mg/mL of GMP, LF, β-C, MFGM-10, β-L, PL-20,
BF or IGEP was also assessed in the miniaturised assay but was graphed separately (Figure 4).
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2.7. Adhesion Assays
HT-29 cells were washed twice with PBS, and 500 µL of the bacteria and media suspensions were
added to the wells, corresponding to approximately 40 bacterial cells per human cell in a 12-well
plate. For the miniaturised assays, 250 µL of the bacteria and media suspensions were added to the
wells, corresponding to approximately 40 bacterial cells per human cell, such that the ratio of bacteria
to HT-29 cell was the same in the 12-well and 48-well assays. Bacterial cells were incubated with
the HT-29 cells for 2 h at 37 ◦C under anaerobic conditions using an Anaerocult A system (Merck).
The HT-29 cells were then washed five times with PBS to remove non-adherent bacteria. HT-29 cells
were then lysed with 250 µL (for 48-well assay) or 500 µL (for 12-well assay) of 1% TritonTM X-100
(Merck) for 5 min at 37 ◦C. The lysates were serially diluted and enumerated by spot-plating on MRS
plates. The adhesion of the bacteria was determined as the percentage of original inoculum which
attached, thus accounting for variations in the starting inoculum. Percentage adhesion = (CFU/mL of
recovered adherent bacteria ÷ CFU/mL of inoculum) × 100. Overall, in this study the percentage of
the original inoculum which adhered to the HT-29 cells was 0.49% ± 0.78%; this is similar to adhesion
rates observed for this strain previously (0.40% ± 0.18%) by Kavanaugh et al. [9]. Adhesion assays
were performed in triplicate on one occasion. Results were presented as the mean of three replicate
experiments graphed as fold-change relative to percent adhesion of the control, with error bars of
one standard deviation of the mean. All figures were generated using unpaired non-parametric t-test
with the exception of Figure 2B where non-parametric one-way Anova multiple comparisons were
used. Statistics were performed using GraphPad Prism version 7.00 for Windows (GraphPad Software,
La Jolla, CA, USA, www.graphpad.com).
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3. Results and Discussion
3.1. Comparison of Conventional and Miniaturised Assays
A miniaturised 48-well adhesion assay was compared with the conventional 12-well adhesion
assay in an effort to reduce the volume of test sample consumption and increase the number of samples
assayed together. Both the 48-well and 12-well assays demonstrated that pre-exposure of the strain
to 5 mg/mL HMO, or a combination of 5 mg/mL 3′- and 6′-SL at a ratio of 1:1, resulted in increased
adhesion to the HT-29 cells (Figure 2) consistent with previous work [8,9]. The 12-well assay resulted in
a 3.4-fold increase in B. infantis adhesion after incubation with HMO, while the 48-well assay resulted
in a 5.7-fold increase in adhesion. Similarly, incubation of B. infantis with 3′- and 6′-SL in the 12-well
assay resulted in a 4.4-fold increase in adhesion, while the 48-well assay resulted in a 3.5-fold increase
in adhesion which demonstrated the scalability of the method. Due to the inherent variability between
adhesion assays, differences in the significance of adhesion rates between the conventional assay and
the miniaturised assay are not unexpected. Thus, the miniaturised assay was comparable to, and as
reproducible as, the conventional colonisation assay.
3.2. Effect of Milk Components on Growth of B. Longum subsp. Infantis ATCC 15697
B. longum subsp. infantis ATCC 15697 (B. infantis) was chosen for this study as it is a
prototypical HMO consumer in the GI tract of the developing infant [16]. Genomic studies
on the strain have demonstrated evolutionary adaptations for the utilisation of milk
glycoconjugates [17] galacto-oligosaccharides (GOS) [18] and fructo-oligosaccharides (FOS) [19],
along with HMO [10,16,18,20,21]. Consumption of such carbohydrates is facilitated by a number
of glycosyl hydrolases and ABC transporters within the strain [16,17], making it a suitable model
strain for this screening study. In this study, no increase in bacterial growth under adhesion assay
conditions (1 h) was observed with the exception of supplementation with β-C, which resulted in
a 47% (p-value: 0.053) increase in cell numbers, and β-L, which resulted in a 17% (p-value: 0.037)
decrease in bacterial cell numbers (Table S1). In whole bovine milk, there are four major forms
of casein, αs1-, αs2-, β- and κ-caseins which make up 38%, 10%, 35% and 12%, respectively [22].
Some of these forms and fractions of these forms have been demonstrated to have growth-promoting
activities [23,24]. Bovine β-L has been shown to have anti-microbial effects against mastitis-causing
bacteria [25]. This anti-microbial effect could help explain the decrease in B. infantis numbers observed
during the 1 h incubation period in the presence of β-L.
3.3. Screening Milk Components for Increased Adhesion of B. longum subsp. Infantis ATCC 15697 to
HT-29 Cells
In order to identify milk components capable of modulating the adhesion of commensal strains
using miniaturised adhesion assays, B. infantis was incubated separately with oligosaccharides isolated
from different sources including human (HMO), goat (GMO), bovine (BMO), and a commercial
prebiotic (Beneo Orafti P95) which acted as a negative control [9], for 1 h at 5 mg/mL, after which
the strain’s ability to adhere to HT-29 was determined. This concentration was selected based on
physiological concentrations of oligosaccharides present in human milk. Bacterial adhesion to HT-29
cells following pre-treatment of the bacteria with GMO resulted in a marked increase in adhesive
ability of the strain (Figure 3), as represented by an 8.3-fold increase in adhesion versus the control.
Previously, B. infantis was shown to have improved adherence following incubation with HMO
using in vitro colonisation models [8,9]. Kavanaugh et al. [9] reported a transcriptional response in
the presence of three different oligosaccharide treatments (3′-SL, 6′-SL and 3′- and 6′-SL combined)
and an overall up-regulation of genes involved in adhesion with a down-regulation of genes involved
in complex oligosaccharide metabolism. However, while that study focused on only HMO and
combinations of 3′- and 6′-SL, the current study is the first to examine the effect of oligosaccharides and
other milk-derived components isolated from domestic animal milks on the adhesive properties
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of B. infantis, thereby potentially overcoming the limitation in the availability of many HMOs.
Each oligosaccharide powder used in this study contained 3′ and 6′ SL (Table 2). In this study,
bacterial cells were incubated with the HT-29 cells for 2 h at 37 ◦C under anaerobic conditions using an
Anaerocult A system (Merck, Dannstadt, Germany). While anaerobic conditions are not optimal for
HT-29 cells, previous studies have demonstrated that minimal negative effects occur within this time
period while allowing for optimal conditions for the bacteria [9].
Table 2. Level of 3′ and 6′ sialyllactose present in the isolated oligosaccharide pools.
Powder 3′ Sialyllactose (µg/mL) 6′ Sialyllactose (µg/mL)
GMO 37.14 35.28
HMO 46.90 59.00
BMO 48.22 26.79
Previous studies have shown that goat milk and human milk share many common oligosaccharide
structures [26] such as β3′-galactosyllactose, β6′-galactosyllactose, 2′-fucosyllactose, lactose-N-hexaose,
6′-N-acetylneuraminyllactose and 3′-N-acetylneuraminyllactose. In fact, the overall oligosaccharide
profile of goat milk is more similar to human milk than either bovine or ovine milk [27]. Added to that,
although goat milk has a substantially lower concentration of oligosaccharides (0.25–0.30 g/L) when
compared to human milk (3–20 g/L), it contains 5 to 8 times more oligosaccharides than bovine milk
(0.03–0.06 g/L) and 10 times more than ovine milk (0.02–0.04 g/L), [27,28]. Interestingly, GMOs have
previously been shown to have other positive biological effects. For instance, GMOs can modulate the
immune response [29,30] and have also been shown to promote the growth of probiotic bacteria [31].
The current study further highlights their potential for inclusion in formulations where breastfeeding
is not possible. Currently, many formulations based on goat milk are on the market, and methods for
the large-scale isolation of GMOs have been investigated, which may allow future clinical trials [32].
In contrast to the other oligosaccharide powders under investigation, pre-treatment with P95
(0.12-fold decrease) or BMO (0.1-fold increase) did not result in a statistically significant change in
adhesion of B. infantis to the intestinal cells (Figure 4). P95 had no effect on B. infantis adhesion in the
study performed by Kavanaugh et al. [9], therefore the result obtained in this study is not surprising.
The BMO powder, however, contains high quantities of 3′- and 6′-SL (Table 2) with minimal lactose and
therefore may be expected to positively influence the adhesion of the strain. This result suggests that in
contrast to pure 3′- and 6′-SL, which seem to have a synergistic effect on adhesion [9], the combination
of multiple oligosaccharides within the BMO pool had no effect on the adhesion capacity of the strain
and may actually inhibit the activity of 3′- and 6′-SL in promoting adhesion.
In this study, apart from free oligosaccharides, IGEP, which is an IgG enriched powder from bovine
whey, also enhanced adhesion of B. infantis to intestinal cells by 3.3-fold (Figure 4). Numerous studies
have highlighted IgG’s bioactivity, specifically its anti-infective capabilities [33,34]. IgG binds to many
gastrointestinal pathogens including Shigella flexneri, Escherichia coli, Clostridium difficile, Streptococcus
mutants, Cryptosporidium parvum, Helicobacter pylori, and rotavirus [35]. Indeed, the main role of
milk IgG is to agglutinate bacteria, neutralise toxins, inactivate viruses and provide an environment
favourable for the growth of beneficial bacteria [34,36]. Considering the immunomodulatory and
bacterial binding properties of IgG, IGEP, which is particularly rich in IgG, may promote adhesion of
B. infantis by acting as a bridging molecule through interacting with both the mammalian and bacterial
cells simultaneously. Alternatively, B. infantis is known to encode an endoglycosidase, EndoBI-1
(glycosyl hydrolase family 18), which cleaves many major types of N-linked oligosaccharides found
on glycoproteins and could thus release intact oligosaccharides from immunoglobulin [37], thereby
providing free oligosaccharides which may function similarly to HMO. However, further studies are
required to investigate whether this is a possibility.
Statistically significant reductions in bifidobacterial adhesion were observed with exposure to LF,
which resulted a 40% reduction in adhesion (p-value: 0.0151), the butter milk fraction, which resulted
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in a 34% reduction (p-value: 0.0002), and PL-20, which resulted in a 37% decrease (p-value: <0.0001)
(Figure 4). As mentioned, Kavanaugh et al. [9] reported an up-regulation in genes associated with
adhesion, and a down-regulation in genes associated with oligosaccharide consumption following
a 3 h pre-incubation period with 3′- and 6′-SL. The components resulting in reduced adhesion of
the strain following the 1 h pre-incubation period could potentially cause B. infantis to preferentially
up-regulate genes involved in carbohydrate metabolism, rather than use energy on adhesion activities.
However, no increase in growth was observed within the 1 h incubation period in this work with the
exception of β-C (Table S1). LF is known to have prebiotic abilities, promoting the growth of various
lactobacilli [38], and antimicrobial activity [39,40], and also displays anti-adhesive effects against
pathogens [41,42]. Further investigations are required to explain the decrease in adhesion observed in
the current study.
The buttermilk fraction and PL-20 are rich in glycoproteins and are associated with many bioactive
properties. Previously, milk fat globule membrane glycoproteins were shown to have anti-adhesive
properties against a range of pathogens including rotavirus and various enteric bacteria [12,36,43,44].
Again, given the carbohydrate-rich nature of constituent glycoproteins, the bacteria may favour
carbohydrate consumption rather than adhesion when incubated with the buttermilk fraction and
PL-20. This however has yet to be confirmed, as significant increases in growth were not observed
in the 1 h pre-treatment period (Table S1). Another consideration is that commensal strains often
adhere to cells using the same host ligands as employed by pathogens [9,45]. As many of the milk
components used in this study which resulted in reduced adhesion of the bifidobacterial strain are
also anti-adhesive against pathogens, it may be that they are competing with the colonisation factors
expressed by B. infantis to colonise the host.
In this study, high molecular weight compounds, such as lactoferrin, β-lactoglobulin and the
buttermilk fraction resulted in a decrease in bifidobacterial adhesion. However, it is important to
note that under conditions, these would likely be digested by the host prior to reaching the colon and
therefore could potentially confer different biological effects to those observed in vitro. In contrast,
the oligosaccharides tested in this study resulted in an increase in adhesion. Milk oligosaccharides
are known to resist digestion, and thus can reach the colon where their presence can influence the
development of a healthy gut microbiota. While IGEP is a high molecular weight protein that can be
partially digested by the host, the resulting glycopeptides may still have bioactive effects on adhesion.
4. Conclusions
Considering the implications of human-derived products such as HMO and 3′- and 6′-SL,
inclusion of GMO as a food ingredient in infant formulations to boost numbers of bifidobacteria
could be a viable alternative, particularly considering the growing popularity of formulas based on
goat milk. Bovine IGEP is relatively easy to isolate and is currently being produced by dairy companies
in Europe for use as a food ingredient. In addition, while this research indicates the potential effects
that milk-derived components may have on the gut microbiota, more supporting data are required.
Future studies to investigate the effects that these powders may have on the colonisation of other gut-
associated commensal and pathogenic bacteria are necessary. This study provides insight into the
role milk components may have modulating commensal transient adhesion, as well as highlighting
alternatives to HMO and 3′- and 6′-SL which are more commercially attractive to produce on a large
scale. In addition, these results demonstrated that miniaturised assays are a feasible alternative to
conventional assays where the yield of bioactive compounds is too low to support a conventional
study. As the plate counting method is time-consuming and can be variable, fluorescent-labeling of the
bacteria to measure the bacteria adhering using a fluorimeter and/or qPCR may improve the efficiency
and yield of the miniaturised assay.
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